TrialCurveREGIRI: reconstructed Kaplan–Meier curves
Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II study. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | ESMO Open. 2025 May 12;10(5):105096. doi: 10.1016/j.esmoop.2025.105096 |
|---|---|
| DOI | 10.1016/j.esmoop.2025.105096 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Overall survival
From figure panel A · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: IRI arm 8.2 months; REGIRI arm 6.3 months. Survival at 6 months: IRI arm 60%; REGIRI arm 55%. Hazard ratio IRI arm vs REGIRI arm 0.90 (95% CI 0.58–1.40).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| IRI arm | 45 | 40 | 8.2 |
| REGIRI arm | 44 | 39 | 6.3 |
- IRI arm vs REGIRI arm: reconstructed HR 0.90 (95% CI 0.58–1.40)
Landmark survival (reconstructed)
| Time | IRI arm | REGIRI arm |
|---|---|---|
| 6 mo | 60.0% | 54.5% |
| 12 mo | 23.3% | 25.0% |
| 18 mo | 7.4% | 11.4% |
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/regiri-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/regiri-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: ESMO Open. 2025 May 12;10(5):105096. doi: 10.1016/j.esmoop.2025.105096 doi:10.1016/j.esmoop.2025.105096. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/regiri
Report a problem with these data
Related trials
- STARGATE: Overall survival; Progression-free survival (blinded central radiologic review)
- Gastrectomy and second-line chemotherapy in advanced gastric cancer: Overall survival; Overall survival (IPTW-adjusted); Progression-free survival; Progression
- KEYNOTE-590 (Japanese subgroup, extended follow-up): Overall survival; Progression-free survival
- JACOB (Chinese subgroup): Overall survival; Progression-free survival (investigator-assessed)
- RATIONALE-306 (Japanese subgroup, 3-year): Overall survival; Progression-free survival (investigator assessment)
- ATTRACTION-2 (2-year update): Overall survival; Progression-free survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials